|
Purpose
The Committee advises the Commissioner and designees on
strategies and programs designed to communicate with the public
about the risks and benefits of FDA-regulated products so as to
facilitate optimal use of these products. The Committee also reviews
and evaluates research relevant to such communication to the public
by both FDA and other entities. It also facilitates interactively
sharing risk and benefit information with the public to enable
people to make informed independent judgments about use of
FDA-regulated products.
Meeting Information
Contact
Lee L. Zwanziger, Designated Federal
Official Office of Commissioner 5600 Fisher Lane,
Rm. 15-22 Rockville, MD 20857 email:
Lee.Zwanziger@fda.hhs.gov phone: 301-827-2895
Committee Membership
The committee shall consist of a core of 15 voting members
including the Chair. Members will be appointed as Special Government
Employees except for members representing industry interests.
Members and the chair are selected by the Commissioner or designee
from among authorities knowledgeable in the fields of risk
communication, social marketing, health literacy, cultural
competency, journalism, bioethics, and other relevant behavioral and
social sciences. Some members will be selected to provide
experiential insight on the communication needs of the various
groups who use FDA-regulated products. The latter may include
patients and patients' family members, health professionals,
communicators in health, medicine and science, and persons
affiliated with consumer, specific disease, or patient safety
advocacy groups. Depending on the meeting topic(s), at least one
nonvoting member identified with relevant industry interests may be
invited from existing members of other FDA Advisory Committees.
Committee Resources
|
|
|
|
|
|
|